You are here

News

February 21, 2014
A Focus on Acute Infection Studies

The study of acute HIV infection is critical to the design and development of HIV vaccines and strategies to achieve an undetectable level of virus without antiretrovirals, or a functional cure. By diagnosing HIV within weeks or even days of infection, scientists are afforded the opportunity to study the early events following infection. This provides the opportunity to look at what the virus...

February 18, 2014
MHRP Diagnostics: A Unique Capability within the DoD

MHRP’s Department of Laboratory Diagnostics and Monitoring (DLDM) conducts state-of-the-art HIV and HIV-related infections diagnostics and cutting-edge diagnostic research. The diagnostics program boasts unique capabilities that aren’t replicated within the Department of Defense (DoD). The following is a Q&A with MHRP Diagnostics Chief, Sheila Peel, MSPH, Ph.D.

What is DLDM’s...

February 5, 2014
New study shows that antibodies seen in RV144 may also correlate with lower risk of infection from multiple HIV subtypes

In a study published in PloS One February 4, researchers show that vaccine-induced antibodies targeted at a particular region of the HIV virus, V1V2, correlate with reduced risk of infection but also react not just with the HIV subtype that was most commonly seen in RV144 (the Thai trial), but also with multiple HIV subtypes that circulate in other parts of the world.

This research was...

February 4, 2014
MHRP Welcomes Dr. Jintanat Ananworanich as Associate Director for Therapeutics Research

MHRP is pleased to announce that Dr. Jintanat Ananworanich has joined MHRP in a newly created position, as Associate Director for Therapeutics Research and member of MHRP’s leadership team.

Dr. Ananworanich will oversee adult HIV therapeutic trials as part of the newly-funded MHRP Clinical Trials Unit under the AIDS Clinical Trials Group (ACTG). She will play a critical role in the...

January 10, 2014
Former MHRP Leader Selected as Next U.S. Global AIDS Coordinator

The White House has nominated Dr. Deborah Birx to be the new U.S. Global AIDS Coordinator succeeding Dr. Eric Goosby who left the position in November. Reporting to the Secretary of State, Dr. Birx will coordinate and oversee the U.S. global response to HIV/AIDS, specifically the programs of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Prior to this nomination, Dr. Birx...

December 18, 2013
MHRP Named a Clinical Trials Unit for NIH HIV/AIDS Clinical Trials Networks

Seven-year award will advance HIV vaccine and therapeutics research at four MHRP sites in Africa

The U.S. Military HIV Research Program, based at the Walter Reed Army Institute of Research, has been selected as a Clinical Trials Unit (CTU) with four clinical research sites that will receive funding from the National Institute of Allergy and Infectious Diseases (NIAID) to continue HIV...

December 6, 2013
World AIDS Day 2013

Thailand

The Thailand ECHO clinic team represented AFRIMS Retrovirology in Pattaya's annual World AIDS Day parade, an event organized by the Pattaya city council. Pattaya is the hometown of the Thailand ECHO clinic and a Thai resort/vacation destination with a large population of MSM and transgender women working in the tourist and service industries with an ongoing high incidence of...

November 15, 2013
DoD Leadership Visits MHRP's Nigeria Research Site

Department of Defense Assistant Secretary for Health, Dr. Jonathan Woodson, paid a visit to MHRP’s site in Nigeria, the Walter Reed Program-Nigeria (WRP-N). While there, Assistant Secretary Woodson presided over the re-commissioning of two boreholes, which provide clean water to the community.

The boreholes, located in Tafa in Kaduna State, were originally constructed by WRP-N and...

November 1, 2013
PEPFAR's Impact After 10 Years

Launched in 2003, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) is the largest effort by any nation to combat a single disease. PEPFAR, which began as an emergency response to AIDS in low-resource settings, is now focused on advancing the sustainability of the response. The program directly supports more than 5 million people on antiretroviral treatment—up from 1.7 million in...

October 24, 2013
Researchers Design Global HIV Vaccine that Shows Promise in Early Studies

The worldwide diversity of HIV poses a critical challenge for designing a globally-effective HIV vaccine. In a new study published October 24 in the journal Cell, a scientific team has shown that bioinformatically optimized HIV vaccine antigens known as “mosaic” antigens might be useful in the design of a global HIV vaccine.

“In this study, we show for the first time that...

Pages